ResearcherNational Hospital Organization Takasaki General Medical CenterActive in the last 2 years

Hidetoshi Yasuoka

Verified by OpenAlex author ID (good confidence, 0.85), identity_conf@1As of 7 November 2026

Matched on OpenAlex author ID A5088169631. Sources: OpenAlex.

Their work

Papers: 2
Trials: 0
Grants: 0
Labs led: 0
Collaborators: 6

Papers, trials and grants by year

2022: 1 paper · 2023: none · 2024: none · 2025: none · 2026: 1 paper

Papers 2

Clinical Utility of the Apolipoprotein A2 Isoform Index as a Tumor Marker for Pancreatic Cancer. Co-author DOI 10.1002/jgh3.70375 ↗
Efficacy and Safety of the Combination of Nano-Liposomal Irinotecan and 5-Fluorouracil/L-Leucovorin in Unresectable Advanced Pancreatic Cancer: A Real-World St… Co-author DOI 10.1159/000525742 ↗

Closest collaborators

The 6 strongest of 6 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

Takashi Hoshino · 2 shared papers, 2022–2026 · strength 0.44
- Paper Clinical Utility of the Apolipoprotein A2 Isoform Index as a Tumor Marker for Pancreatic Cancer. DOI 10.1002/jgh3.70375 ↗
- Paper Efficacy and Safety of the Combination of Nano-Liposomal Irinotecan and 5-Fluorouracil/L-Leucovorin in Unresectable Adv… DOI 10.1159/000525742 ↗
Satoru Kakizaki · 2 shared papers, 2022–2026 · strength 0.44
- Paper Clinical Utility of the Apolipoprotein A2 Isoform Index as a Tumor Marker for Pancreatic Cancer. DOI 10.1002/jgh3.70375 ↗
- Paper Efficacy and Safety of the Combination of Nano-Liposomal Irinotecan and 5-Fluorouracil/L-Leucovorin in Unresectable Adv… DOI 10.1159/000525742 ↗
Shomei Ryozawa · 1 shared paper, 2026 · strength 0.32
- Paper Clinical Utility of the Apolipoprotein A2 Isoform Index as a Tumor Marker for Pancreatic Cancer. DOI 10.1002/jgh3.70375 ↗
Norihiro Ishii · 1 shared paper, 2022 · strength 0.12
- Paper Efficacy and Safety of the Combination of Nano-Liposomal Irinotecan and 5-Fluorouracil/L-Leucovorin in Unresectable Adv… DOI 10.1159/000525742 ↗
Kenichiro Araki · 1 shared paper, 2022 · strength 0.12
- Paper Efficacy and Safety of the Combination of Nano-Liposomal Irinotecan and 5-Fluorouracil/L-Leucovorin in Unresectable Adv… DOI 10.1159/000525742 ↗
Ken Shirabe · 1 shared paper, 2022 · strength 0.12
- Paper Efficacy and Safety of the Combination of Nano-Liposomal Irinotecan and 5-Fluorouracil/L-Leucovorin in Unresectable Adv… DOI 10.1159/000525742 ↗

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.